Macromolecular Therapeutics Development


The Macromolecular Therapeutics Development Facility (MTDF) provides expertise for directed development and optimization of protein-based therapeutics and supports high-throughput automated development, analysis and production of protein reagents using a Bioemk FxP  liquid handling workstation for HTP molecular biology and expression testing, a Perkin-Elmer Cell::Explorer robot for very efficient HTP tissue culture based application and a custom microarray printer. This automation is designed to provide Einstein researchers with the added leverage of robotics equipment and trained personnel to accelerate and scale up their projects, thereby obviating the need for individual investigators to set up and staff their own facilities for protein production.


  • General cloning into a range of protein expression vectors (single through 96 well)
  • Expression profiling – E. coli, insect, mammalian
  • Large-scale and high-throughput growth of cells or bacteria expressing recombinant proteins
  • Classical and automated purification of recombinant proteins from culture supernatant
  • Custom DNA and cell microarrays
  • Generation of hybridomas making mouse and rat monoclonal antibodies
  • Generation of isotype switched monoclonal antibodies

Location and Contacts

Macromolecular Therapeutics Development

Price Center/Block Research Pavillion 313


Scientific Director
Steven C. Almo, Ph.D.

Operations Director
Scott Garforth, Ph.D.

Co-Scientific Director (Monoclonal Antibodies)
Matthew D. Scharff, M.D.

Associate Director (Monoclonal Antibodies)
Susan Buhl